Curi RMB Capital LLC Boosts Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Curi RMB Capital LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,070 shares of the company's stock after purchasing an additional 1,499 shares during the period. Curi RMB Capital LLC's holdings in IDEXX Laboratories were worth $2,923,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IDXX. Hurley Capital LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Crews Bank & Trust purchased a new position in IDEXX Laboratories during the fourth quarter worth about $41,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX traded down $3.54 during trading on Friday, hitting $437.44. 939,200 shares of the stock were exchanged, compared to its average volume of 631,554. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The stock has a fifty day moving average price of $420.16 and a two-hundred day moving average price of $429.68. The firm has a market capitalization of $35.45 billion, a P/E ratio of 41.00, a PEG ratio of 3.41 and a beta of 1.50.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IDXX shares. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $523.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.